Shares of Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN) have earned a consensus broker rating score of 1.30 (Strong Buy) from the five analysts that cover the company, Zacks Investment Research reports. Two analysts have rated the stock with a buy rating and three have issued a strong buy rating on the company.

Analysts have set a 12-month consensus price target of $33.40 for the company and are anticipating that the company will post ($0.57) EPS for the current quarter, according to Zacks. Zacks has also assigned Biohaven Pharmaceutical Holding Co an industry rank of 108 out of 265 based on the ratings given to related companies.

A number of brokerages have recently commented on BHVN. Morgan Stanley began coverage on shares of Biohaven Pharmaceutical Holding Co in a report on Wednesday, May 31st. They issued an “overweight” rating for the company. Needham & Company LLC started coverage on shares of Biohaven Pharmaceutical Holding Co in a report on Tuesday, May 30th. They issued a “buy” rating and a $30.00 target price for the company. William Blair started coverage on shares of Biohaven Pharmaceutical Holding Co in a research note on Tuesday, May 30th. They set an “outperform” rating and a $46.00 price target on the stock. Piper Jaffray Companies started coverage on shares of Biohaven Pharmaceutical Holding Co in a research note on Tuesday, May 30th. They set an “overweight” rating and a $21.00 price target on the stock. Finally, Barclays PLC started coverage on shares of Biohaven Pharmaceutical Holding Co in a research note on Tuesday, May 30th. They set an “overweight” rating and a $30.00 price target on the stock.

In related news, CFO James Engelhart bought 2,500 shares of the stock in a transaction on Tuesday, May 9th. The shares were bought at an average cost of $17.00 per share, for a total transaction of $42,500.00. Following the completion of the transaction, the chief financial officer now owns 3,576 shares of the company’s stock, valued at approximately $60,792. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Albert Cha bought 470,000 shares of the stock in a transaction on Tuesday, May 9th. The shares were bought at an average price of $17.00 per share, for a total transaction of $7,990,000.00. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 472,550 shares of company stock worth $8,033,350.

Shares of Biohaven Pharmaceutical Holding Co (NASDAQ BHVN) traded up 1.70% during midday trading on Monday, reaching $23.98. The company’s stock had a trading volume of 45,162 shares. The company has a 50 day moving average of $25.21 and a 200-day moving average of $23.84. The stock’s market capitalization is $857.24 million. Biohaven Pharmaceutical Holding Co has a 52 week low of $17.00 and a 52 week high of $28.34.

COPYRIGHT VIOLATION NOTICE: This report was published by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/08/07/zacks-biohaven-pharmaceutical-holding-co-ltd-nasdaqbhvn-given-33-40-consensus-price-target-by-analysts.html.

About Biohaven Pharmaceutical Holding Co

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Get a free copy of the Zacks research report on Biohaven Pharmaceutical Holding Co (BHVN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Biohaven Pharmaceutical Holding Co (NASDAQ:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related companies with MarketBeat.com's FREE daily email newsletter.